Skip to main content

Table 2 Cumulative PPV/Sensitivity/Specificity (%) for CIN2+ in the triage of hrHPV-positive women

From: Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination

hrHPV types Primary type For the new type CIN2+/HPV+ Cumulative types
PPV (%) CIN2+/HPV+ PPV (%) PPV (%) SEN (%) SPE (%)
16 27.4 279/1020 27.4 279/1020 27.4 63.8 67.8
33 26.0 28/119 23.5 307/1139 27.0 70.3 63.8
35 17.6 10/59 16.9 317/1198 26.5 72.5 61.7
58 18.2 46/292 15.8 363/1490 24.4 83.1 51.0
31 16.8 18/127 14.2 381/1617 23.6 87.2 46.2
68 9.9 8/121 6.6 389/1738 22.4 89.0 41.3
18 8.3 16/265 6.0 405/2003 20.2 92.7 30.5
56 10.4 5/84 6.0 410/2087 19.6 93.8 27.0
52 11.7 15/270 5.6 425/2357 18.0 97.3 15.9
66 5.7 4/74 5.4 429/2431 17.6 98.2 12.9
51 7.2 5/131 3.8 434/2562 16.9 99.3 7.4
59 7.9 2/56 3.6 436/2618 16.7 99.8 5.0
45 10.3 1/32 3.1 437/2650 16.5 100.0 3.7
39 4.9 0/85 0.0 437/2735 16.0 100.0 0.0
  1. Abbreviations: CIN2+ cervical intraepithelial neoplasia 2 or worse, SEN sensitivity, SPE specificity, PPV positive predictive value